PMID- 20923473
OWN - NLM
STAT- MEDLINE
DCOM- 20110202
LR  - 20221207
IS  - 1753-0407 (Electronic)
IS  - 1753-0407 (Linking)
VI  - 2
IP  - 1
DP  - 2010 Mar
TI  - Lack of effect of subtherapeutic vitamin D treatment on glycemic and lipid 
      parameters in Type 2 diabetes: A pilot prospective randomized trial.
PG  - 36-40
LID - 10.1111/j.1753-0407.2009.00057.x [doi]
AB  - BACKGROUND: Epidemiological studies suggest a higher prevalence of metabolic 
      syndrome and its components among individuals with vitamin D deficiency. The aim 
      of the present study was to determine whether vitamin D treatment improves 
      glucose control and insulin sensitivity in Type 2 diabetes mellitus (T2DM). 
      METHODS: Subjects with T2DM and serum 25-hydroxyvitamin D (25(OH)D) 
      concentrations <25 ng/mL were randomized to receive 400 IU (Group 1) or 1200 IU 
      (Group 2) cholecalciferol for 4 months. Fasting plasma glucose, glycosylated 
      hemoglobin (HbA1c), Quantitative Insulin Sensitivity Check Index (QUICKI), serum 
      lipid levels and serum adiponectin were measured at baseline and at 4 months. 
      RESULTS: Mean 25(OH)D levels increased in both groups (from 17.6+/-1.5 to 25.5+/-1.8 
      ng/mL in Group 1 and from 15.6+/-1.4 to 27.4+/-2.4 ng/mL in Group 2; P</=0.001 vs 
      baseline for each group). No significant differences were noted in fasting plasma 
      glucose, HbA1c, QUICKI, serum adiponectin, and lipid levels compared with 
      baseline within groups or between the two groups. CONCLUSIONS:   In the present 
      pilot study, conventional vitamin D treatment at a level improving, but not 
      optimizing, serum 25(OH)D did not improve glycemia, insulin sensitivity, or lipid 
      profile. However, diabetes and lipids were relatively well controlled at 
      baseline. Future studies should be designed to achieve optimal concentrations of 
      serum 25(OH)D (at least >32 ng/mL) and should include subjects showing more 
      abnormal parameters of glycemia, lipid, and insulin sensitivity at baseline.
CI  - (c) 2010 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and 
      Blackwell Publishing Asia Pty Ltd.
FAU - Patel, Parini
AU  - Patel P
AD  - Division of Endocrinology and Friedman Diabetes Institute, Department of 
      Medicine, Beth Israel Medical Center, New York, New York, USA.
FAU - Poretsky, Leonid
AU  - Poretsky L
FAU - Liao, Emilia
AU  - Liao E
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20091005
PL  - Australia
TA  - J Diabetes
JT  - Journal of diabetes
JID - 101504326
RN  - 0 (Adiponectin)
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Insulin)
RN  - 0 (Lipids)
RN  - 0 (Triglycerides)
RN  - 1406-16-2 (Vitamin D)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - A288AR3C9H (25-hydroxyvitamin D)
SB  - IM
MH  - Adiponectin/blood
MH  - Blood Glucose/drug effects/*metabolism
MH  - Cholesterol/blood
MH  - Diabetes Mellitus, Type 2/*blood
MH  - Ethnicity
MH  - Female
MH  - Glycated Hemoglobin/drug effects/metabolism
MH  - Humans
MH  - Insulin/blood
MH  - Lipids/*blood
MH  - Male
MH  - Metabolic Syndrome/etiology
MH  - Middle Aged
MH  - Pilot Projects
MH  - Prospective Studies
MH  - Triglycerides/blood
MH  - Vitamin D/*analogs & derivatives/blood/pharmacology
MH  - Vitamin D Deficiency/complications
EDAT- 2010/10/07 06:00
MHDA- 2011/02/03 06:00
CRDT- 2010/10/07 06:00
PHST- 2010/10/07 06:00 [entrez]
PHST- 2010/10/07 06:00 [pubmed]
PHST- 2011/02/03 06:00 [medline]
AID - 10.1111/j.1753-0407.2009.00057.x [doi]
PST - ppublish
SO  - J Diabetes. 2010 Mar;2(1):36-40. doi: 10.1111/j.1753-0407.2009.00057.x. Epub 2009 
      Oct 5.